CN104812415A - 药物组合 - Google Patents
药物组合 Download PDFInfo
- Publication number
- CN104812415A CN104812415A CN201380061889.8A CN201380061889A CN104812415A CN 104812415 A CN104812415 A CN 104812415A CN 201380061889 A CN201380061889 A CN 201380061889A CN 104812415 A CN104812415 A CN 104812415A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- methyl
- acceptable salt
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)C(CC(C)[C@@]1(C)[C@@](C)C1N)C*=O Chemical compound CC(C)C(CC(C)[C@@]1(C)[C@@](C)C1N)C*=O 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731174P | 2012-11-29 | 2012-11-29 | |
| US61/731,174 | 2012-11-29 | ||
| US201261731555P | 2012-11-30 | 2012-11-30 | |
| US61/731,555 | 2012-11-30 | ||
| US201361755520P | 2013-01-23 | 2013-01-23 | |
| US61/755,520 | 2013-01-23 | ||
| PCT/US2013/071852 WO2014085381A1 (en) | 2012-11-29 | 2013-11-26 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104812415A true CN104812415A (zh) | 2015-07-29 |
Family
ID=49753513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380061889.8A Pending CN104812415A (zh) | 2012-11-29 | 2013-11-26 | 药物组合 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9446043B2 (https=) |
| EP (1) | EP2925366B1 (https=) |
| JP (1) | JP6437444B2 (https=) |
| CN (1) | CN104812415A (https=) |
| AU (1) | AU2013352379B2 (https=) |
| BR (1) | BR112015012497B1 (https=) |
| CA (1) | CA2892578C (https=) |
| DK (1) | DK2925366T3 (https=) |
| ES (1) | ES2669248T3 (https=) |
| HU (1) | HUE037618T2 (https=) |
| NZ (1) | NZ708802A (https=) |
| PL (1) | PL2925366T3 (https=) |
| RU (1) | RU2674995C2 (https=) |
| TR (1) | TR201806682T4 (https=) |
| UA (1) | UA115250C2 (https=) |
| WO (1) | WO2014085381A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201904851D0 (en) | 2019-04-05 | 2019-05-22 | Katholieke Univ Leven | Melanoma treatment |
| US11086278B2 (en) | 2019-08-29 | 2021-08-10 | Inventus Holdings, Llc | Adaptive system monitoring using incremental regression model development |
| US20240207257A1 (en) * | 2021-04-15 | 2024-06-27 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
| US20260083731A1 (en) * | 2022-08-26 | 2026-03-26 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma with a pkc inhibitor |
| GB202408599D0 (en) * | 2024-06-14 | 2024-07-31 | Vasopharma Ab | Combination treatments |
| GB202408598D0 (en) * | 2024-06-14 | 2024-07-31 | Edvince Ab | Combination treatments |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652776A (zh) * | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489608A (en) | 1989-12-21 | 1996-02-06 | Goedecke Aktiengesellschaft | Indolocarbazole derivatives and the use thereof |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| NO308798B1 (no) | 1993-12-07 | 2000-10-30 | Lilly Co Eli | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| YU49315B (sh) | 1995-11-20 | 2005-06-10 | Elli Lilly And Company | Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| US6645970B2 (en) | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| AU2002221810B2 (en) * | 2000-11-07 | 2005-06-23 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| AU2006268908A1 (en) | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
-
2013
- 2013-11-26 BR BR112015012497-6A patent/BR112015012497B1/pt active IP Right Grant
- 2013-11-26 CN CN201380061889.8A patent/CN104812415A/zh active Pending
- 2013-11-26 TR TR2018/06682T patent/TR201806682T4/tr unknown
- 2013-11-26 UA UAA201505167A patent/UA115250C2/uk unknown
- 2013-11-26 CA CA2892578A patent/CA2892578C/en active Active
- 2013-11-26 US US14/647,939 patent/US9446043B2/en active Active
- 2013-11-26 ES ES13802815.4T patent/ES2669248T3/es active Active
- 2013-11-26 HU HUE13802815A patent/HUE037618T2/hu unknown
- 2013-11-26 RU RU2015124954A patent/RU2674995C2/ru active
- 2013-11-26 NZ NZ70880213A patent/NZ708802A/en unknown
- 2013-11-26 AU AU2013352379A patent/AU2013352379B2/en active Active
- 2013-11-26 WO PCT/US2013/071852 patent/WO2014085381A1/en not_active Ceased
- 2013-11-26 JP JP2015545170A patent/JP6437444B2/ja active Active
- 2013-11-26 EP EP13802815.4A patent/EP2925366B1/en active Active
- 2013-11-26 PL PL13802815T patent/PL2925366T3/pl unknown
- 2013-11-26 DK DK13802815.4T patent/DK2925366T3/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652776A (zh) * | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
Non-Patent Citations (4)
| Title |
|---|
| PATRICE LEE ET.AL: "Abstract 2515：Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor", 《CANCER RESEARCH》 * |
| STN: "Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations", 《CAPLUS》 * |
| XINQI WU ET.AL: "Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-kB Pathways", 《MOL CANCER THER》 * |
| XINQI WU ET.AL: "The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma", 《PLOS ONE》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215789A1 (en) | 2016-09-15 |
| EP2925366A1 (en) | 2015-10-07 |
| UA115250C2 (uk) | 2017-10-10 |
| HUE037618T2 (hu) | 2018-09-28 |
| BR112015012497A2 (pt) | 2017-07-11 |
| BR112015012497A8 (pt) | 2019-10-01 |
| TR201806682T4 (tr) | 2018-06-21 |
| AU2013352379A1 (en) | 2015-06-11 |
| AU2013352379B2 (en) | 2018-09-06 |
| RU2015124954A (ru) | 2017-01-11 |
| RU2674995C2 (ru) | 2018-12-14 |
| JP6437444B2 (ja) | 2018-12-12 |
| EP2925366B1 (en) | 2018-02-21 |
| JP2016501222A (ja) | 2016-01-18 |
| NZ708802A (en) | 2019-09-27 |
| BR112015012497B1 (pt) | 2022-05-17 |
| WO2014085381A1 (en) | 2014-06-05 |
| CA2892578C (en) | 2021-01-12 |
| CA2892578A1 (en) | 2014-06-05 |
| DK2925366T3 (en) | 2018-06-06 |
| US9446043B2 (en) | 2016-09-20 |
| PL2925366T3 (pl) | 2018-08-31 |
| US20150306101A1 (en) | 2015-10-29 |
| ES2669248T3 (es) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2433476T3 (es) | Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos | |
| US9675595B2 (en) | Synergistic combinations of PI3K- and MEK-inhibitors | |
| AU2019278886B2 (en) | Composition and method of treating cancer associated with EGFR mutation | |
| US20090239881A1 (en) | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments | |
| CN104994850A (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| US20160129003A1 (en) | Pharmaceutical Combinations | |
| RU2674995C2 (ru) | Фармацевтические комбинации | |
| EP3007693A1 (en) | Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent | |
| CN113329749B (zh) | 用于治疗葡萄膜黑色素瘤的联合疗法 | |
| EP4203963B1 (en) | Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma | |
| US20050176725A1 (en) | Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer | |
| WO2014174478A1 (en) | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor | |
| EP1811988B1 (en) | Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction | |
| HK1215789B (en) | Pharmaceutical combinations | |
| WO2017013271A1 (en) | Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150729 |